Male Health Drug Development Pipeline Comprehensive and Therapeutic Development Reviewed 2017

To Understand the Pharmaceutical Industry Status worldwide, Market Research Hub (MRH) has included the latest Forecast report titled “Male Health Drug Development Pipeline Review, 2017”, to its vast database. This report provides an overview of the pipeline landscape for male health. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Male Hypogonadism, Erectile Dysfunction and Benign Prostatic Hyperplasia, and features dormant and discontinued projects. Male hypogonadism is a condition in which the body doesnt produce enough testosterone, resulting in signs and symptoms of testosterone deficiency and/or infertility. Symptoms include fatigue, hot flashes, infertility, decrease in muscle mass and loss of bone mass (osteoporosis).

Request For Free Sample Report: https://www.marketresearchhub.com/enquiry.php?type=S&repid=1343223

Erectile dysfunction is the inability of a man to achieve and sustain an erection sufficient to have sexual intercourse. It can also be known as impotence. The predisposing factors include tobacco usage, overweight, injuries, drug and alcohol use and medications, including antidepressants, antihistamines and medications to treat high blood pressure, pain or prostate cancer.

Benign prostatic hyperplasia is the enlargement of the prostate gland and occurs when cells of the prostate gland begin to multiply. Symptoms include painful urination, leakage of urine, nocturia and blood in the urine.

The size of these pipelines ranges from 23 products in male hypogonadism to 36 in erectile dysfunction. Across all three of these indications, however, androgen receptors and phosphodiesterase 5 are the most common targets, closely reflecting the current treatment landscape of these diseases.

Scope

- Which companies are the most active within the pipeline for male health therapeutics?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in the field of male health?
Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Browse Full Report with TOC: https://www.marketresearchhub.com/report/male-health-drug-development-pipeline-review-2017-report.html

Table of Content:
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 7
2 Introduction 8
2.1 Male Health Report Coverage 8
2.2 Male Hypogonadism - Overview 8
2.3 Erectile Dysfunction - Overview 8
2.4 Benign Prostatic Hyperplasia - Overview 8
3 Therapeutics Development 9
3.1 Male Hypogonadism 9
3.2 Erectile Dysfunction 15
3.3 Benign Prostatic Hyperplasia 22
4 Therapeutics Assessment 29
4.1 Male Hypogonadism 29
4.2 Erectile Dysfunction 36
4.3 Benign Prostatic Hyperplasia 43
5 Companies Involved in Therapeutics Development 52
5.1 Male Hypogonadism 52
5.2 Erectile Dysfunction 58
5.3 Benign Prostatic Hyperplasia 71
6 Dormant Projects 84
6.1 Male Hypogonadism 84
6.2 Erectile Dysfunction 85
6.3 Benign Prostatic Hyperplasia 88
7 Discontinued Products 90
7.1 Male Hypogonadism 90
7.2 Erectile Dysfunction 90
7.3 Benign Prostatic Hyperplasia 91
8 Product Development Milestones 92
8.1 Male Hypogonadism 92
8.2 Erectile Dysfunction 103
8.3 Benign Prostatic Hyperplasia 111
9 Appendix 124
9.1 Methodology 124
9.2 Coverage 124
9.3 Secondary Research 124
9.4 Primary Research 124
9.5 Expert Panel Validation 124
9.6 Contact Us 125
9.7 Disclaimer 125

1.1 List of Tables
Table 1: Number of Products under Development for Male Hypogonadism, H2 2017 9
Table 2: Number of Products under Development by Companies, H2 2017 11
Table 3: Number of Products under Development by Universities/Institutes, H2 2017 12
Table 4: Products under Development by Companies, H2 2017 13
Table 5: Products under Development by Universities/Institutes, H2 2017 14
Table 6: Number of Products under Development for Erectile Dysfunction, H2 2017 15
Table 7: Number of Products under Development by Companies, H2 2017 17
Table 8: Number of Products under Development by Universities/Institutes, H2 2017 18
Table 9: Products under Development by Companies, H2 2017 19
Table 10: Products under Development by Universities/Institutes, H2 2017 21
Table 11: Number of Products under Development for Benign Prostatic Hyperplasia, H2 2017 22
Table 12: Number of Products under Development by Companies, H2 2017 24
Table 13: Number of Products under Development by Universities/Institutes, H2 2017 25
Table 14: Products under Development by Companies, H2 2017 26
Table 15: Products under Development by Universities/Institutes, H2 2017 28
Table 16: Number of Products by Stage and Target, H2 2017 30
Table 17: Number of Products by Stage and Mechanism of Action, H2 2017 32
Table 18: Number of Products by Stage and Route of Administration, H2 2017 34
Table 19: Number of Products by Stage and Molecule Type, H2 2017 36
Table 20: Number of Products by Stage and Target, H2 2017 37
Table 21: Number of Products by Stage and Mechanism of Action, H2 2017 39
Table 22: Number of Products by Stage and Route of Administration, H2 2017 41
Table 23: Number of Products by Stage and Molecule Type, H2 2017 43
Table 24: Number of Products by Stage and Target, H2 2017 45
Table 25: Number of Products by Stage and Mechanism of Action, H2 2017 47
Table 26: Number of Products by Stage and Route of Administration, H2 2017 49
Table 27: Number of Products by Stage and Molecule Type, H2 2017 51
Table 28: Male Hypogonadism - Pipeline by Antares Pharma Inc, H2 2017 52
Table 29: Male Hypogonadism - Pipeline by Clarus Therapeutics Inc, H2 2017 52
Table 30: Male Hypogonadism - Pipeline by EndoCeutics Inc, H2 2017 53
Table 31: Male Hypogonadism - Pipeline by Ferring International Center SA, H2 2017 53
Table 32: Male Hypogonadism - Pipeline by Lipocine Inc, H2 2017 54
Table 33: Male Hypogonadism - Pipeline by M et P Pharma AG, H2 2017 54
Table 34: Male Hypogonadism - Pipeline by Medlab Clinical Ltd, H2 2017 55
Table 35: Male Hypogonadism - Pipeline by Merck & Co Inc, H2 2017 55
Table 36: Male Hypogonadism - Pipeline by Mereo Biopharma Group Plc, H2 2017 56
Table 37: Male Hypogonadism - Pipeline by Repros Therapeutics Inc, H2 2017 56
Table 38: Male Hypogonadism - Pipeline by TesoRx Pharma LLC, H2 2017 57
Table 39: Male Hypogonadism - Pipeline by The Female Health Company, H2 2017 58
Table 40: Male Hypogonadism - Pipeline by Viramal Ltd, H2 2017 58
Continue…..

Enquire About This Report: https://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1343223

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of pharmaceutical market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us

90 State Street,
Albany, NY 12207,
United States

Toll Free: 800-998-4852 (US-Canada)
Email: press@marketresearchhub.com
Website: http://www.marketresearchhub.com/
Read Industry News at - https://www.industrynewsanalysis.com/

This release was published on openPR.